National Engineering Laboratory for Anti-Tumor Protein Therapeutics, Beijing 100084, China.
Front Med. 2011 Dec;5(4):336-40. doi: 10.1007/s11684-011-0163-5. Epub 2011 Dec 27.
Endostatin, a 20 kDa C-terminal fragment of collagen XVIII, was first identified as a potent angiogenic inhibitor. The anti-angiogenic function of endostatin has been well documented during the past decade. Recently, several studies demonstrated that endostatin also inhibits tumor lymphangiogenesis and lymphatic metastasis. However, the exact mechanism that endostatin executes its anti-angiogenic and anti-lymphangiogenic functions remains elusive. In the current mini-review, we briefly summarize recent novel findings, including the functions of endostatin targeting not only angiogenesis but also lymphangiogenesis, and the underlying mechanism by which endostatin internalization regulates its biological functions.
内皮抑素是胶原 XVIII 的一个 20kDa C 末端片段，最初被鉴定为一种有效的血管生成抑制剂。在过去的十年中，内皮抑素的抗血管生成功能得到了充分的证明。最近，一些研究表明内皮抑素也抑制肿瘤淋巴管生成和淋巴转移。然而，内皮抑素执行其抗血管生成和抗淋巴管生成功能的确切机制仍不清楚。在本综述中，我们简要总结了最近的新发现，包括内皮抑素的作用不仅针对血管生成，还针对淋巴管生成，以及内皮抑素内化调节其生物学功能的潜在机制。
